Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2017-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the efficacy of clinical nutrition to treat lung neoplasms and breast carcinoma.We estimate there will be 480 patients accepted.120 patients will receive GLSE compound,120 patients will recrive Maitake mushroom extract compound,120 patients will recrive Rinseng compound,and 120 patients will be as blank countrol group.Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Compound Amino Acid Tablets on Nutritional Status of Patients With Lung Cancer

NCT05770063

Amino Acid Deficiency Malnutrition Lung Cancer

UNKNOWN NA

Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

NCT05834413

Lung Cancer

NOT_YET_RECRUITING NA

Investigation of the Contents and Prognostic Values of Glucose Metabolism Molecules in Patients With Lung Adenocarcinoma

NCT03641105

Lung Cancer Glycolysis Diagnosis +1 more

UNKNOWN

Nutritional Status and Clinical Outcomes in Patients With Common Malignancies(NCOM)

NCT06219083

Cancer Chemoradiotherapy Nutrition, Healthy +2 more

RECRUITING

Gut Microbiota and Cancer Immunotherapy Response

NCT04682327

Non-Small Cell Lung Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

GLSE compound、Maitake mushroom extract compound and Rinseng compound have different mechanism on enhancing immunity.This clinicaltrial compare them the immune effect in the progress of treating lung neoplasms and breast carcinoma.Within the 42 days,we will abide by the plan to evaluate the immunity enhancement by monitoring mmune effector molecules.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasms Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GLSE compound group

GLSE compound 2g each time by mouth,twice a day for 42 days.

Group Type EXPERIMENTAL

GLSE compound

Intervention Type DRUG

Maitake mushroom extract compound group

Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.

Group Type EXPERIMENTAL

Maitake mushroom extract compound

Intervention Type DRUG

Ginseng compound group

Ginseng compound 2 tables each time by mouth,twice a day for 42 days.

Group Type EXPERIMENTAL

Ginseng compound

Intervention Type DRUG

blank control group

Take nothing.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLSE compound

Intervention Type DRUG

Maitake mushroom extract compound

Intervention Type DRUG

Ginseng compound

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* lung cancer and breast cancer patients confirmed by surgery pathology;
* ECOG physical stamina score of 0\~3 points;
* Expected lifetime \> 3 months;
* Need to receive radiation and chemotherapy;
* Heart, liver and kidney function and blood picture is normal,WBC≥4×109/L, neutrophil count≥ 2 x 109 / L,platelet count≥100×109/L, hemoglobin≥100 g/L;
* To follow-up, good adherence

Exclusion Criteria

* Allergic to text drug;
* Pregnancy or lactation women;
* Suffering from mental illness of not easy to control,
* Have serious mental or cognitive dysfunction;
* Can not comply with the experimental scheme or can't cooperate with the follow-up;
* The patients who are unfavorable to the subject.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No